Literature DB >> 29973656

Downreguation of FoxM1 by miR-214 inhibits proliferation and migration in hepatocellular carcinoma.

Chuan Tian1,2, Haixia Wu2, Chan Li3, Xia Tian2, Yong Sun4, Enqiang Liu5, Xiuyong Liao5, Wei Song6.   

Abstract

The FoxM1 transcription factor plays an important role in the progression of HCC. Therefore, it is necessary to study cell regulation of FoxM1. In this study, we determined the expression of miR-214 and it was inversely associated with FoxM1 protein level in HCC; and suppression of FoxM1 translation by miR-214 mimics. We found that miR-214 targeted the 3'untranslated region of FoxM1 mRNA. In addition, the study found that DLX1 was the direct target of FoxM1 in HCC. Downregulation of FoxM1 inhibits the proliferation, migration, and invasion of HCC cells by miR-214. These results indicate that miR-214 may be used as a completely new molecular target by influencing FoxM1 expression in HCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29973656     DOI: 10.1038/s41434-018-0029-4

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

1.  Bioinformatical identification of key genes regulated by IGF2BP2-mediated RNA N6-methyladenosine and prediction of prognosis in hepatocellular carcinoma.

Authors:  Qiang Wei
Journal:  J Gastrointest Oncol       Date:  2021-08

2.  Reduced expression of microRNA-139-5p in hepatocellular carcinoma results in a poor outcome: An exploration the roles of microRNA-139-5p in tumorigenesis, advancement and prognosis at the molecular biological level using an integrated meta-analysis and bioinformatic investigation.

Authors:  Hui Qin; Dong-Yue Wen; Qiao Que; Chuan-Yang Zhou; Xiao-Dong Wang; Yu-Ting Peng; Yun He; Hong Yang; Bo-Ming Liao
Journal:  Oncol Lett       Date:  2019-11-01       Impact factor: 2.967

3.  MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.

Authors:  Jing-Ran Sun; Xiao Zhang; Ya Zhang
Journal:  Cell Mol Biol Lett       Date:  2019-12-04       Impact factor: 5.787

4.  FOXM1 functions collaboratively with PLAU to promote gastric cancer progression.

Authors:  Chao Ai; Jixin Zhang; Shenyi Lian; Jie Ma; Balázs Győrffy; Zhenyuan Qian; Yong Han; Qin Feng
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

Review 5.  Roles of Thyroid Hormone-Associated microRNAs Affecting Oxidative Stress in Human Hepatocellular Carcinoma.

Authors:  Po-Shuan Huang; Chia-Siu Wang; Chau-Ting Yeh; Kwang-Huei Lin
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

6.  Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1.

Authors:  Deeptashree Nandi; Pradeep Singh Cheema; Aakriti Singal; Hina Bharti; Alo Nag
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

7.  FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells.

Authors:  Kenly Wuputra; Pi-Jung Hsiao; Wen-Tsan Chang; Po-Hsuan Wu; Lin-Ann Chen; Jian-Wei Huang; Wen-Lung Su; Ya-Han Yang; Deng-Chyang Wu; Kazunari K Yokoyama; Kung-Kai Kuo
Journal:  Int J Mol Sci       Date:  2022-07-14       Impact factor: 6.208

8.  miR-877-5p Suppresses Gastric Cancer Cell Proliferation Through Targeting FOXM1.

Authors:  Kun Wu; Zhu Yu; Zhenyong Tang; Weiyuan Wei; Dongyi Xie; Yubo Xie; Qiang Xiao
Journal:  Onco Targets Ther       Date:  2020-05-26       Impact factor: 4.147

9.  Based on Integrated Bioinformatics Analysis Identification of Biomarkers in Hepatocellular Carcinoma Patients from Different Regions.

Authors:  Linxin Teng; Kaiyuan Wang; Yu Liu; Yanxia Ma; Weiping Chen; Lei Bi
Journal:  Biomed Res Int       Date:  2019-10-28       Impact factor: 3.411

10.  HELLS Is Negatively Regulated by Wild-Type P53 in Liver Cancer by a Mechanism Involving P21 and FOXM1.

Authors:  Stefanie Schuller; Jan Sieker; Philip Riemenschneider; Bianca Köhler; Elisabeth Drucker; Sofia M E Weiler; Daniel Dauch; Carsten Sticht; Benjamin Goeppert; Stephanie Roessler; Silvia Ribback; Kai Breuhahn; Falko Fend; Frank Dombrowski; Kerstin Singer; Stephan Singer
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.